2024-07-24 23:07:14 ET
Summary
- IHE invests in large-cap U.S. pharmaceutical stocks with solid long-term growth outlook but high concentration risk.
- IHE's fund price has been steady with a positive trend in 2024, but its elevated valuation may not make it a good buy currently.
- Despite being a defensive play in an economic recession, IHE can still experience significant declines due to market sentiment.
Introduction
Read the full article on Seeking Alpha
For further details see:
IHE: Significant Growth Ahead, But Valuation Not Cheap (Rating Downgrade)